Subtype
Prostate Adenocarcinoma
CI-CAN-00003766PRADExplore in graph →
133 active trials1 approved drugs3 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003766PRADExplore in graph →
Clinical trials
433 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (71)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | terminated | Phase 3 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | terminated | Phase 3 | 38 | Timothy HoffmanFED | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03327662 | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer(CTC-STOP) | terminated | Phase 3 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 6, 2021 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2023source: clinicaltrials